EmTheraPro

EmTheraPro develops diagnostic assays for Alzheimer’s and other neurodegenerative conditions. The company’s novel approach, originating at Emory University, uses precision proteomics, in which a proteins from cerebrospinal fluid are analyzed as biomarkers using an assay. This allows medical providers to detect pathologies associated with neurodegenerative disease.

By integrating protein analysis with complementary clinical, pathological and genetic data, EmTheraPro’s approach strives toward the full potential of precision medicine to treat neurodegenerative diseases. As of 2022, Alzheimer’s diagnostics the annual growth rate for the $100 million+ market was estimated at 30%.